Janssen Biotech's Zytiga improved survival and delayed cancer growth for 18 months when added to standard care in a study of 1,200 men with advanced prostate cancer. The drug is approved to treat tumors that are resistant to hormone therapy; this study ...
Study: Black and white men with prostate cancer prioritize treatment ...
When it comes to making decisions about which prostate cancer treatment to choose, black and white men prioritize certain treatment-related factors differently, ...
No comments:
Post a Comment